Corcept Therapeutics Incorporated - Common Stock - fluxo de caixa (NASDAQ:CORT)

Financials

Fluxo de caixa operacional 151.97 M167.89 M120.32 M127.04 M198.07 M142 M 120.45 M Fluxo de caixa de investimento -119.26 M136.13 M-114.33 M90.91 M-177.6 M69.76 M 77.47 M Fluxo de caixa de financiamento 12.21 M-302.59 M-17.28 M-148.72 M-28.35 M-220.37 M -179.8 M Fluxo de caixa livre 151.97 M167.89 M120.32 M127.04 M198.07 M141.78 M 120.15 M

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

CORT

Financials

Corcept Therapeutics Incorporated - Common Stock

Notícias

Corcept apresenta dados de sobrevivência para tratamento de câncer de ovário

CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock Up

Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to Trade

Will Korlym Continue to Aid CORT's Growth in 2026 After a Strong Q1?

S&P 500 and Nasdaq 100 Post New Record Highs on Chip Stock Strength

Chip Stock Strength Lifts the Broader Market

Stocks Pressured by Signs of Resurgent Inflation

Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement (NASDAQ:CORT)

H.C. Wainwright eleva preço-alvo das ações da Corcept após guidance de receita

CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised

Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates

Resultados da Corcept em foco: novo medicamento contra câncer pode compensar perdas?